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Physician Fee Schedule and represented in 2013 US dollars. Average wholesale prices 
for a 30-day supply of AA and ENZA were $7,674 and $8,940, respectively. One-way 
sensitivity analyses were performed against all probability, utility, and cost values 
incorporated into this cost-effectiveness model. Results: In this analysis, AA pro-
vides substantial saving with $13,322 per patient versus ENZA. The main drivers 
of the model are drug costs, health utility values, and efficacy (OS and rPFS). The 
robustness of the results was supported by sensitivity analyses. ConClusions: 
Given similar OS benefits, AA is cost saving compared with ENZA for the treatment 
of patients with mCPRC post-docetaxel based on US data.
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objeCtives: Pharmacoeconomic evaluations are more critical in developing 
countries in which economic effects of new and expensive therapies have sig-
nificant impact on patients, insurance companies and the health systems. Since 
cost-effectiveness studies are too costly and time consuming, in these countries 
new medications are often being used in daily practice before being well docu-
mented as cost-effective interventions. This would force health organizations 
to perform comparative studies as alternatives to cost-effectiveness analysis. 
Trastuzumab, an anti-cancer monoclonal antibody which was approved by FDA 
in 1998, is an expensive medicine introduced to the Iranian pharmaceutical market 
since 2003, with an annual usage cost of 308,352,730,640 Rials ($ US 25,000,000) in 
2010. Methods: A systematic review on electronic medical databases including 
the Cochrane, CRD, EMBASE, HEED, MEDLINE, and PubMed, covering the years 2000 
to 2009, was performed using relevant key words to extract publications investi-
gating cost-effectiveness and efficacy of trastuzumab in breast cancer treatment. 
The Incremental Cost-Effectiveness Ratios (ICERs) were compared with a criterion 
introduced by WHO. Results: The reported ICERs were between $90,118/QALY 
to $217,264/QALY and $13,361/QALY to $65,250/QALY in metastatic and adjuvant 
breast cancer therapy, respectively. The metastatic ICERs were 8 to 20 folds of the 
GDP per Capita in Iran whereas the adjuvant phase ICERs were 1.2 to 6 folds of it. 
Sensitivity analysis showed the results are more sensitive to discount rate, drug 
regimen cost, duration of survival benefits, as well as the risk of relapse and metas-
tasis. ConClusions: Trastuzumab therapy in metastatic breast cancer cannot be 
cost effective in Iran, however as adjuvant therapy it is still a challenging issue. 
Unlimited access to this medicine would not be rational and recommendations 
with an approach to optimize its usage, e.g. administration in younger patients 
with poor prognosis and higher risk of relapse or using clean rooms to reduce drug 
wasting, are strongly advised.
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objeCtives: To determine the cost-effectiveness of bendamustine-rituximab 
(Ben-R) versus fludarabine-rituximab (Fdb-R) in patients with iNHL who have pro-
gressed following treatment with rituximab or a rituximab-containing regimen in 
Mexico. Methods: An economic model was constructed from the Mexican public 
payer perspective, with a 35-year (lifetime) horizon and a discount rate of 5%. The 
model included three health states, progression-free (PF), progressive disease (PD), 
and death, which were associated with utility weights of 0.81, 0.62 and 0, respec-
tively. Clinical inputs (response rates, Kaplan-Meier curves, hazard ratios (HRs) and 
adverse event rates) were from the Stil NHL 2-2003 study. Resource use data were 
from interviews with Mexican hematologists treating iNHL patients. Unit costs were 
obtained from Mexican Social Security Institute (IMSS) and were expressed as 2013 
Mexican Pesos. Univariate and probabilistic sensitivity analyses were conducted to 
determine the key drivers of cost-effectiveness, and uncertainty around the results, 
respectively. Results: Total cost of Ben-R was $1,726,828 and total cost of Fdb-R 
was $1,640,024. Ben-R patients accrued more LYs (5.82 vs. 4.73), QALYs (4.22 vs. 3.29), 
and PF LYs (3.37 vs. 1.96) compared to Fdb-R patients. The ICERs were $79,890 (cost 
per LY), $92,788 (cost per QALY) and $61,486 (cost per PF LY). Univariate sensitivity 
analysis revealed that the ICER per LY was most sensitive to the PF survival (PFS) and 
overall survival (OS) HRs for Ben-R vs Fdb-R and the use of bone marrow transplants 
in the PD state. Probabilistic sensitivity analysis with 1,000 iterations estimated that 
Ben-R will be cost effective over 90% of the time at a willingness-to-pay threshold 
of $125,085. ConClusions: At a willingness-to-pay of $125,085 (GDP per capita of 
Mexico) Ben-R is cost effective versus Fdb-R.
PCN111
a CoSt-effeCtiveNeSS aNalySeS of uSiNg SuNitiNib (Su) iN firSt liNe of 
metaStatiC reNal CaNCer iN romaNiaN JuriSdiCtioN
Berghea F.1, Skoupa J.2, Ciuleanu T.3, Miron L.4, Stanculeanu D.L.5, Jinga D.6, Dediu M.5, 
Mateescu D.N.7, Hájek P.8, Bradatan B.9, Xuan J.10
1Carol Davila University Of Medicine and Pharmacy, Bucharest, Romania, 2ISPOR Chapter Czech 
Republic, Prague 7, Czech Republic, 3Ion Chiricuta Clinic, Cluj, Romania, 4Oncology Institute, 
Iasi, Romania, 5“Alexandru Trestioreanu” Oncology Institute, Bucharest, Romania, 6University 
Hospital, Bucharest, Romania, 7Diagnosis & Treatment Oncology Center, Brasov, Romania, 8Pfizer, 
Praha, Czech Republic, 9Pfizer, Bucharest, Romania, 10Pfizer, Inc., New York, NY, USA
objeCtives: In Romania the estimated incidence of metastatic renal cancer 
(mRCC) is about 1500 cases; less than 400 patients receive full reimbursement for 
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objeCtives: To provide an overview on published decision-analytic models 
evaluating treatment strategies for multiple myeloma (MM) focusing on the cost-
effectiveness results. Methods: A systematic literature search was performed in 
the electronic databases Pubmed, NHS EED and the Tufts CEA Registry to identify 
studies evaluating MM treatment strategies using mathematical decision-analytic 
models. To meet the inclusion criteria, models were required to compare different 
treatment strategies, to be published as full text articles in English, and com-
prise relevant clinical health outcomes over a defined time horizon and popula-
tion. We used evidence tables to summarize methodological characteristics and 
economic results. For comparability, all economic results were transferred into 
2012 US Dollar. We used Purchasing Power Parity to convert the currency into US 
Dollar of the same year. For converting US Dollar from step one into US Dollars 
2012, we used Consumer Price Index rates for the relevant year. Results: We 
found eleven decision-analytic modeling studies. Economic evaluations were 
included in all studies. Eight studies reported cost-utility results. The modeling 
approaches applied included a decision tree model, Markov cohort model, discrete 
event simulations, partitioned survival analyses and area under the curve models. 
Time horizons ranged from seven years to lifetime. Half of the models chose the 
perspective of the health care system, while other perspectives were societal, 
third party payer and government payer. Among others, two studies reported cost-
effectiveness of autologous transplantation vs. standard-dose melphalan with an 
ICER of $31,263 /life-year gained (LYG) and $36,778/LYG. One study reported that 
bortezomib vs. lenalidomide plus dexamethasone is cost saving, while another 
comparable study reported an ICUR for lenalidomide plus dexamethasone vs. 
bortezomib of $22,301/QALY. ConClusions: We identified several well-designed 
cost-effectiveness/cost-utility models using a broad variety of different modeling 
approaches. Results of most of the studies were not comparable due to different 
treatment strategies, target population and settings.
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objeCtives: To examine the empirical and methodological cost-effectiveness evi-
dence of surgical interventions for breast, colorectal, and prostate cancer. Methods: 
Systematic searches of seven databases including MEDLINE, EMBASE, CDSR,HTA, 
DARE, EconLit and NHSEED, research registers, the National Institute of Health and 
Care Excellence (NICE) website and conference proceedings was conducted in April 
2012. Studies were included if they evaluated the cost-effectiveness of a surgical 
procedure in either breast, colorectal or prostate cancer and reported cost per quality 
adjusted life-year or cost per life-year results. The quality of the studies included was 
assessed in terms of meeting essential, preferred, and UK specific requirements for 
economic evaluations. Results: The 17 (breast= 3,colorectal= 7,prostate= 7) studies 
which satisfied the inclusion criteria covered a broad range of settings with 9 set in 
European and 8 in non-European locations. Just a third (11/17) was published within 
the last 10 years. In terms of the essential quality criteria; the populations, inter-
ventions and comparators were generally well defined. However, very few studies 
were informed by the results of literature reviews or synthesised clinical evidence. 
Although the interventions had potential differential effects on recurrence and mor-
tality rates, some studies used relatively short time horizons. Although univariate 
sensitivity analyses were reported in all studies, less than a third characterised all 
uncertainty with a probabilistic sensitivity analysis. While a third of studies incorpo-
rated patients’ health-related quality of life data, only 4 of the 17 studies used social 
tariff values. ConClusions: There is very little recent robust evidence describing 
the cost-effectiveness of surgical interventions in these indications. Many of the 
more recent publications did not satisfy the essential methods requirements, such 
as using synthesising clinical evidence informed by a systematic literature review. 
Given the ratio of potential benefit and harm associated with surgery in cancer, there 
is an urgent need to conduct additional robust economic evaluations in this area.
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objeCtives: With approvals of abiraterone acetate (AA) and enzalutamide (ENZA) 
in the past 2 years, the treatment landscape has shifted dramatically for metastatic 
castration-resistant prostate cancer (mCRPC) patients who failed docetaxel-based 
chemotherapy. There is increasing interest in the relative cost-effectiveness of these 
therapies. The objective of this study was to assess the cost-effectiveness of AA 
versus ENZA among individuals with mCRPC post chemotherapy from a payer per-
spective. Methods: A survival-based Markov cohort model consisting of 3 health 
states, progression-free, progressed, and dead, was developed to project over 10 
year period. Progression between states was determined by overall survival (OS) 
and radiographic progression free survival (rPFS). An indirect treatment comparison 
was conducted to determine the relative efficacy of AA and ENZA (data reported 
separately). Utilities were mapped from FACT-P to EQ-5D based on a review of the 
literature. Drug acquisition costs in the US were used since ENZA was approved only 
in the US at the time of analysis. Costs of scheduled and unscheduled follow-up 
visits were obtained from the Centers for Medicare Services Drug Payment Table and 
